Irbesartan Sandoz (Irbesartan)

Irbesartan belongs to the class of Angiotensin II receptor blockers and is used to manage conditions related to the renin‑angiotensin system.

• Hypertension: lowers blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney disease in patients with type 2 diabetes.
• Cardiovascular risk reduction: helps lower the chance of stroke and heart attack in hypertensive individuals.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal tissue, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This inhibition leads to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure.

Irbesartan may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Hyperkalemia: elevated potassium levels detected in blood tests.
• Cough: occasional dry throat irritation.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing.
• Acute renal failure: sudden loss of kidney function.
• Hepatic injury: abnormal liver enzyme elevations or hepatitis.
• Severe hypotension: markedly low blood pressure causing fainting.
• Neutropenia: dangerously low white blood cell count.
• Anaphylaxis: life‑threatening allergic reaction with rash, wheezing, and shock.

Before initiating therapy with Irbesartan, certain precautions should be observed.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before and during treatment.
• Serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents.
• Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk.
• Hepatic impairment: use with caution in patients with liver disease.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with several other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use may increase renal dysfunction.
• Dual ARB/ACE inhibitor therapy: heightened risk of hyperkalemia and renal impairment.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous potassium elevation.
• NSAIDs (e.g., ibuprofen): can reduce renal perfusion and worsen kidney function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance antihypertensive effect, leading to hypotension.
• Lithium: increased lithium levels and toxicity risk.
• Cyclosporine: may potentiate nephrotoxic effects.
• Rifampin: may lower Irbesartan plasma concentrations, reducing efficacy.